Salix Pharmaceuticals, Ltd. Announces Submission of Granulated Mesalamine New Drug Application

Published: Dec 31, 2007

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) seeking approval to market granulated mesalamine. Salix believes this application will be subject to a 10-month review period.

Back to news